Quarterly report [Sections 13 or 15(d)]

Acquisitions, Licensing and Other Arrangements - Pulmokine Acquisition (Details)

v3.25.1
Acquisitions, Licensing and Other Arrangements - Pulmokine Acquisition (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Nov. 30, 2024
Mar. 31, 2025
Mar. 31, 2024
Asset acquisition      
Amortization of intangible assets   $ 544  
Net Income (Loss)   2,367 $ (8,595)
Revenue from contracts with customers   4,000 $ 1,000
Pulmokine      
Asset acquisition      
Closing cash payment $ 20,500    
Estimated useful life 12 years    
Amortization of intangible assets   500  
Impairment of intangible asset   0  
Contract assets   0  
Contract liabilities   0  
Revenue from contracts with customers   $ 0